Clinical Trial Update: MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating multi-immune, multi-target immunotherapy for high-risk multiple myeloma is planned but not yet recruiting. The sponsor is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma (MM) | Phase 2 | Status: NOT_YET_RECRUITING